Author:
Emery Paul,Van Keep Marjolijn,Beard Steve,Graham Chris,Miles LaStella,Jugl Steffen Marc,Gunda Praveen,Halliday Anna,Marzo-Ortega Helena
Funder
Novartis Pharmaceuticals UK Limited
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference24 articles.
1. McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ (Clin Res Ed). 2006;333(7568):581–5.
https://doi.org/10.1136/bmj.38954.689583.DE
.
2. National Ankylosing Spondylitis Society. Ankylosing spondylitis (AS) guidebook. London: National Ankylosing Spondylitis Society; 2012.
3. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–5.
https://doi.org/10.1136/ard.2011.151191
.
4. Hamilton L, Barkham N, Bhalla A, Brittain R, Cook D, Jones G, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxf, Engl). 2017;56(2):313–6.
https://doi.org/10.1093/rheumatology/kew223
.
5. National Institute for Health and Care Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). Technology Appraisal Guidance. London: National Institute for Health and Care Excellence; 2016.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献